Online citations, reference lists, and bibliographies.
← Back to Search

Anti-Citrullinated Protein Antibodies As Novel Therapeutic Drugs In Rheumatoid Arthritis

R. G. Chirivi, G. Jenniskens, J. Raats
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
We have developed a novel antibody-based treatment for rheumatoid arthritis. In a collagen antibody-induced arthritis mouse model, anti-citrullinated protein antibodies (ACPAs) prevent the onset and/or exacerbation of inflammation, and prevent or strongly reduce joint damage. For the development of this novel therapy, we focussed on rheumatoid arthritis-specific citrullinated peptide epitopes. A growing number of studies indicate that modifications of arginines into citrulline residues are responsible for the initial triggering of autoimmunity and the breaking of tolerance. We identified a subset of human recombinant ACPAs that prevent the onset of inflammation in both collagen-induced arthritis and collagen antibody-induced arthritis mouse models for rheumatoid arthritis. Therapeutic administration of these antibodies resulted in the arrest of the inflammation and prevented a further increase of the inflammatory response. Prophylactic administration significantly prevented the onset of inflammation. Histological analysis of inflamed joints from ACPA treated mice revealed a significant decrease in joint damage, as compared to control animals. To identify the differentiating therapeutic epitope recognized by the therapeutic ACPA (tACPA), we performed comparative immunoprecipitations with therapeutic and non-therapeutic ACPAs using human PAD4- deiminated HEK-293 cell lysates, followed by mass spectrometry analysis. The differentiating peptide epitope that is recognized by tACPAs only, is a citrullinated domain of Histone-2A. A second generation of antibodies was selected against this domain by means of phage display and by hybridoma generation. The second generation of tACPAs was comprised of even more potent inhibitors of the inflammatory response. Here, we describe the identification of a series of antibodies directed against a citrullinated epitope present in murine and human histone-2A. In mouse models for rheumatoid arthritis we demonstrate that these tACPAs exhibit a strong anti-inflammatory activity and prevent the occurrence of swelling and joint damage. We propose anti-histone-2A tACPA as a novel therapeutic treatment for rheumatoid arthritis patients.
This paper references
Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor FcγRIIB
S. Petkova (2006)
Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice
Jonathan A. Hill (2008)
Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis.
L. Lutteri (2007)
Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation
Y. Wang (2009)
Citrullination under physiological and pathological conditions.
Z. Baka (2012)
Diagnostic utility of anticitrullinated protein antibody and its comparison with rheumatoid factor in rheumatoid arthritis
AH Khan (2012)
Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation.
C. Foulquier (2007)
JCCI, an open access journal Immunotherapies and Rheumatoid arthritis
Knotting the NETs: Analyzing histone modifications in neutrophil extracellular traps
Indira Neeli (2012)
Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides.
W. Stemmer (1995)
Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility.
K. Takeuchi (2012)
Weight Gain and Hair Loss during Anti-TNF Therapy
Abdo Lutf (2012)
Liquid chromatography-mass spectrometry-based proteomics of Nitrosomonas.
H. Wessels (2011)
The late adverse events of rituximab therapy – rare but there!
Ron Ram (2009)
Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis.
Andrew J Kinloch (2008)
Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins.
N. Bizzaro (2007)
Potential Role of Peptidylarginine Deiminase Enzymes and Protein Citrullination in Cancer Pathogenesis
Sunish Mohanan (2012)
PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures
Marc Leshner (2012)
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
X. Chang (2006)
Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis
D. Makrygiannakis (2012)
Role for peptidylarginine deiminase enzymes in disease and female reproduction.
Sachi Horibata (2012)
Citrullination: a posttranslational modification in health and disease.
B. György (2006)
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
S. Rantapää-Dahlqvist (2003)
Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis.
K. Kuhn (2006)
Correction: Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies
C. Liu (2012)
Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis
Cheng-Tao Yang (2012)
Histone citrullination by protein arginine deiminase: is arginine methylation a green light or a roadblock?
P. Thompson (2006)
Determinants of NSAID choice in rheumatoid arthritis--a drug utilization study.
A. Inotai (2012)
Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry
M. Wilm (1996)
PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease
E. Vossenaar (2003)
Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis.
J. Raats (2003)
Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis
H. Uysal (2009)
Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.
A. Chumanevich (2011)
Histone Deimination As a Response to Inflammatory Stimuli in Neutrophils1
Indira Neeli (2008)
Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein*S
Y. Ishihama (2005)
Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis
E. Vossenaar (2004)
N-α-Benzoyl-N5-(2-Chloro-1-Iminoethyl)-l-Ornithine Amide, a Protein Arginine Deiminase Inhibitor, Reduces the Severity of Murine Collagen-Induced Arthritis
V. Willis (2011)
Diagnostic utility of anti-citrullinated protein antibody and its comparison with rheumatoid factor in rheumatoid arthritis.
A. Khan (2012)
Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics.
J. Rappsilber (2003)
Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.
M. Nielen (2004)
The Major Synovial Targets of the Rheumatoid Arthritis-Specific Antifilaggrin Autoantibodies Are Deiminated Forms of the α- and β-Chains of Fibrin1
C. Masson-Bessière (2001)
Inhibiting citrullination in rheumatoid arthritis: taking fuel from the fire
B. Fisher (2012)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar